DK0827408T3 - Fremgangsmåde til administration af IGF-I - Google Patents

Fremgangsmåde til administration af IGF-I

Info

Publication number
DK0827408T3
DK0827408T3 DK96915698T DK96915698T DK0827408T3 DK 0827408 T3 DK0827408 T3 DK 0827408T3 DK 96915698 T DK96915698 T DK 96915698T DK 96915698 T DK96915698 T DK 96915698T DK 0827408 T3 DK0827408 T3 DK 0827408T3
Authority
DK
Denmark
Prior art keywords
administration
mammal
igf
period
time
Prior art date
Application number
DK96915698T
Other languages
Danish (da)
English (en)
Inventor
Neil Gesundheit
Marc R Hammerman
Ross G Clark
Steven B Miller
Original Assignee
Genentech Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Univ Washington filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0827408T3 publication Critical patent/DK0827408T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
DK96915698T 1995-05-22 1996-05-09 Fremgangsmåde til administration af IGF-I DK0827408T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/445,805 US5741776A (en) 1995-05-22 1995-05-22 Method of administration of IGF-I
PCT/US1996/006704 WO1996037216A1 (en) 1995-05-22 1996-05-09 Method of administration of igf-i

Publications (1)

Publication Number Publication Date
DK0827408T3 true DK0827408T3 (da) 2007-02-26

Family

ID=23770265

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96915698T DK0827408T3 (da) 1995-05-22 1996-05-09 Fremgangsmåde til administration af IGF-I

Country Status (16)

Country Link
US (1) US5741776A (ja)
EP (1) EP0827408B1 (ja)
JP (2) JPH11505265A (ja)
AT (1) ATE343395T1 (ja)
AU (1) AU699113B2 (ja)
CA (1) CA2218018A1 (ja)
DE (1) DE69636654T2 (ja)
DK (1) DK0827408T3 (ja)
ES (1) ES2275276T3 (ja)
HK (1) HK1009744A1 (ja)
IL (1) IL118356A0 (ja)
MX (1) MX9708918A (ja)
NZ (1) NZ307913A (ja)
PT (1) PT827408E (ja)
WO (1) WO1996037216A1 (ja)
ZA (1) ZA963995B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
AU1384199A (en) 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
JP2002510646A (ja) 1998-04-03 2002-04-09 カイロン コーポレイション 関節軟骨障害を処置するためのｉｇｆｉの使用
IL143834A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
EP1141014B1 (en) * 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
EP2286792A1 (en) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
DE19951471A1 (de) * 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
PT2274978E (pt) * 2003-09-12 2015-07-09 Ipsen Biopharmaceuticals Inc Métodos para tratamento da deficiência do fator de crescimento de tipo insulina i (igf-i)
EP1846021A2 (en) * 2005-02-08 2007-10-24 Japan As Represented By The President Of National Cardiovascular Center Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
PT2510942E (pt) 2005-04-07 2015-12-28 Cardiorentis Ag Utilização de péptido natriurético para o tratamento de insuficiência cardíaca
EP1901770B1 (en) * 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
ES2325432B1 (es) * 2006-01-13 2010-06-09 Universidad De Malaga Utilizacion de dosis bajas de igf-i en el envejecimiento por sus efectos neuroprotectores, antioxidantes y anabolizantes.
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
DE68905203T2 (de) * 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
DE69327402T2 (de) * 1992-06-12 2000-05-04 Albert Einstein College Of Medicine Of Yeshiva University, Bronx Vorbeugung und behandlung der peripheren neuropathie
EP0661990B1 (en) * 1992-08-26 2002-04-10 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
AU675996B2 (en) * 1992-10-29 1997-02-27 Genentech Inc. Method for treatment or prevention of obesity
EP0642350A4 (en) * 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
CA2172158A1 (en) * 1993-09-20 1995-03-30 Joseph A. Carlino Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I

Also Published As

Publication number Publication date
EP0827408A1 (en) 1998-03-11
AU5740696A (en) 1996-12-11
IL118356A0 (en) 1996-09-12
ZA963995B (en) 1997-11-20
EP0827408B1 (en) 2006-10-25
WO1996037216A1 (en) 1996-11-28
AU699113B2 (en) 1998-11-19
US5741776A (en) 1998-04-21
PT827408E (pt) 2007-01-31
JP2009132682A (ja) 2009-06-18
NZ307913A (en) 2005-07-29
DE69636654T2 (de) 2007-10-04
MX9708918A (es) 1998-06-30
JPH11505265A (ja) 1999-05-18
ATE343395T1 (de) 2006-11-15
CA2218018A1 (en) 1996-11-28
HK1009744A1 (en) 1999-06-11
ES2275276T3 (es) 2007-06-01
DE69636654D1 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
DK0827408T3 (da) Fremgangsmåde til administration af IGF-I
DE3769379D1 (de) Entzuendungshemmende wirkstoffe, pharmazeutische zusammensetzungen und verfahren zur bekaempfung von entzuendungen.
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69221501D1 (de) Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
DK0873312T3 (da) Alfa-substituerede arylsulfonamidohydroxamsyrer som TNF-alfa- og matrix-metalloproteinaseinhibitorer
YU49094B (sh) Postupak za dobijanje sinergističke terapeutske kompozicije
FR2659959B1 (fr) Procede de projection de beton et melange utilise.
DK0918516T3 (da) Fremgangsmåde til forebyggelse af skeletale problemer hos fjerkræ
ATA309588A (de) Neue kristallform von ciclosporin, verfahren zu ihrer herstellung, diese kristallform enthaltende pharmazeutische zusammensetzung und verwendung dieser kristallform
DK0822816T3 (da) Dermatologisk præparat til behandling af actiniske keratoser
FI971711A (fi) Levobupivakaiinin ja sen analogien kiteyttäminen
ES2131528T3 (es) Nuevos polipeptidos y su uso.
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE68918944D1 (de) Künstliche rezeptor-analoge.
DK0809489T3 (da) Lægemiddelform til levering af kollagenase til sår og fremgangsmåde til dens fremstilling
DK2359854T3 (da) Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese
DK0537313T3 (da) Arylalkylestere af 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre med terapeutisk aktivitet
EP0901873A3 (en) Liquid cristal display for laser marker
ATE141789T1 (de) Zusammensetzung enthaltend dibucaine- hydrochlorid, ein salicylat, calciumbromid und ein antiphlogistisches steroid zur schmerzbekämpfung
ATE275414T1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
SE9601264L (sv) Förfarande och anordning för håråterväxt
AT358573B (de) Verfahren zur herstellung von (1,1-dithienyl- -(3-propen-(1)-yl-(3))-(1-phenyl-1-hydroxy- propyl-2))-amin und dessen saeureadditions- salzen und optisch aktiven isomeren
JPS52123195A (en) Driving system of matrix type liquid crystal element